Skip to main content
PMC home page
Trials logoLink to Trials
. 2020 Dec 29;21:1033. doi: 10.1186/s13063-020-04991-y

Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

T Vanassche 1,2,✉, M M Engelen 1,2, Q Van Thillo 3, J Wauters 4, J Gunst 5, C Wouters 6,7, C Vandenbriele 1,2, S Rex 2,8, L Liesenborghs 1,9, A Wilmer 4, P Meersseman 4, G Van den Berghe 5, D Dauwe 5, G Verbeke 10, M Thomeer 11,12, T Fivez 12,13, D Mesotten 12,13, D Ruttens 11, L Heytens 14, I Dapper 15, S Tuyls 16, B De Tavernier 15, P Verhamme 1,2; DAWn consortium members
PMCID: PMC7770739  PMID: 33375932

Correction to: Trials (2020) 21:1005

https://doi.org/10.1186/s13063-020-04878-y

Following publication of the original article [1], we were notified that the figure of the study design in the paper was an older, incorrect figure that did not correctly reflect randomization strategy, patient numbers, and intervention. The incorrect and correct figures are presented below.

  • Originally published figure graphic file with name 13063_2020_4991_Figa_HTML.jpg

  • Corrected figure graphic file with name 13063_2020_4991_Figb_HTML.jpg

The original article has been corrected.

Reference

  • 1.Vanassche T, et al. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020;21:1005. doi: 10.1186/s13063-020-04878-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES